+1,040.6%
NBIS vs GSK
+35.4%
+1,005.2%
-58.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.1% | -1.0% | -4.0% | -5.5% |
| 7D | +8.3% | -5.4% | +13.7% | +6.0% |
| 30D | +18.1% | -4.6% | +22.7% | +16.5% |
| 3M | +7.8% | -5.1% | +12.9% | +6.5% |
| 6M | +136.6% | -11.4% | +148.0% | +131.4% |
| YTD | +172.5% | +0.7% | +171.8% | +176.2% |
| 1Y | +144.3% | +23.0% | +121.2% | +157.0% |
| All | +1,040.6% | +35.4% | +1,005.2% | +1,579.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling